Article
A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1)
Molecular endocrinology (Baltimore, Md.) - 1 Dec 1999
Nazareth L V, Stenoien D L, Bingman W E, James A J, Wu C, Zhang Y, Edwards D P, Mancini M, Marcelli M, Lamb D J, Weigel N L
Abstract excerpt
Androgen ablation therapy is a primary treatment for advanced prostate cancer, but tumors become refractive to therapy. Consequently, the role of the androgen receptors (ARs) and of mutations in the AR in prostate cancer has been a subject of much concern. In the course of analyzing tumors for mutations, we identified a somatic mutation that substitutes tyrosine for a cysteine at amino acid 619 (C619Y), which is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.